Lipomics Technologies, Inc. Sign Research Collaboration Agreement for Pharmacometabolic Markers
5/21/2007 10:28:19 AM
WEST SACRAMENTO, CA -- (MARKET WIRE) -- May 21, 2007 -- Lipomics Technologies, Inc., a privately held company that specializes in the analysis of lipid metabolites, announced today that they have entered into a two year collaborative research agreement with Duke University in several key clinical areas to identify pharmacometabolomic markers. Lipomics will provide Duke analytical services for biomarker discovery and validation (using its proprietary platform and technologies relating to lipid profiles) as well as provide data transfer and interpretation services that will streamline the process of biomarker development allowing researchers at Duke easy access to analysis and data. In return, Lipomics will receive an option to license diagnostic rights on all such markers developed under this agreement through use of Lipomics proprietary technologies. Initial clinical areas are CNS (schizophrenia and depression) and Cardiovascular (response to statins) disorders.
comments powered by